RESUMO
PharmML is an XML-based exchange format created with a focus on nonlinear mixed-effect (NLME) models used in pharmacometrics, but providing a very general framework that also allows describing mathematical and statistical models such as single-subject or nonlinear and multivariate regression models. This tutorial provides an overview of the structure of this language, brief suggestions on how to work with it, and use cases demonstrating its power and flexibility.
Assuntos
Biologia Computacional/métodos , Simulação por Computador , Humanos , Modelos Estatísticos , Dinâmica não Linear , Interface Usuário-ComputadorRESUMO
BioModels is a reference repository hosting mathematical models that describe the dynamic interactions of biological components at various scales. The resource provides access to over 1,200 models described in literature and over 140,000 models automatically generated from pathway resources. Most model components are cross-linked with external resources to facilitate interoperability. A large proportion of models are manually curated to ensure reproducibility of simulation results. This tutorial presents BioModels' content, features, functionality, and usage.
RESUMO
The lack of a common exchange format for mathematical models in pharmacometrics has been a long-standing problem. Such a format has the potential to increase productivity and analysis quality, simplify the handling of complex workflows, ensure reproducibility of research, and facilitate the reuse of existing model resources. Pharmacometrics Markup Language (PharmML), currently under development by the Drug Disease Model Resources (DDMoRe) consortium, is intended to become an exchange standard in pharmacometrics by providing means to encode models, trial designs, and modeling steps.
RESUMO
Diabetes is a chronic and complex multifactorial disease caused by persistent hyperglycemia and for which underlying pathogenesis is still not completely understood. The mathematical modeling of glucose homeostasis, diabetic condition, and its associated complications is rapidly growing and provides new insights into the underlying mechanisms involved. Here, we discuss contributions to the diabetes modeling field over the past five decades, highlighting the areas where more focused research is required.CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e54; doi:10.1038/psp.2013.30; advance online publication 10 July 2013.
RESUMO
Ten patients affected by occlusive arterial disease and presenting with skin lesions of the limbs were treated with buflomedil first i.v. and then orally, at a dosage of 600 mg/day. After a treatment period of 30 to 60 days, eight patients showed lesion regression with complete recovery; the remaining two patients dropped out of the study. The mechanism of action of buflomedil in healing skin lesions is also discussed.